Savara Inc. (SVRA) and Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Contrasting side by side

Savara Inc. (NASDAQ:SVRA) and Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Savara Inc. 6 0.00 N/A -1.36 0.00
Aurinia Pharmaceuticals Inc. 6 1307.20 N/A -0.71 0.00

In table 1 we can see Savara Inc. and Aurinia Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.


Table 2 provides Savara Inc. and Aurinia Pharmaceuticals Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Savara Inc. 0.00% -45.6% -32.6%
Aurinia Pharmaceuticals Inc. 0.00% 0% 0%

Analyst Recommendations

The Recommendations and Ratings for Savara Inc. and Aurinia Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Savara Inc. 0 0 0 0.00
Aurinia Pharmaceuticals Inc. 0 0 5 3.00

Meanwhile, Aurinia Pharmaceuticals Inc.’s consensus price target is $15, while its potential upside is 127.62%.

Institutional & Insider Ownership

Savara Inc. and Aurinia Pharmaceuticals Inc. has shares held by institutional investors as follows: 44.9% and 0%. 1.1% are Savara Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Savara Inc. -1.55% -5.93% -76.42% -66.04% -77.34% -66.45%
Aurinia Pharmaceuticals Inc. 2.42% -1.24% 4.43% 0% 19.77% -6.74%

For the past year Aurinia Pharmaceuticals Inc. has weaker performance than Savara Inc.


Aurinia Pharmaceuticals Inc. beats on 7 of the 8 factors Savara Inc.

Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its product pipeline comprises AeroVanc, a Phase III ready inhaled formulation of vancomycin for the treatment of persistent methicillin-resistant staphylococcus aureus and lung infection in cystic fibrosis patients; Molgradex, a Phase II/III stage inhaled granulocyte-macrophage colony-stimulating factor for the treatment of autoimmune pulmonary alveolar proteinosis; and Aironite, an inhaled nebulized sodium nitrite solution to treat heart failure with preserved ejection fraction. The company is headquartered in Austin, Texas.

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc. and 3SBio, Inc. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.